Peptides At The Crossroads: FDA Tightens The Line As Category 2 Pushes Toward Category 1

Peptides are no longer operating in the background of compounding pharmacy practice. They are now front and center, and more importantly, under a level of scrutiny that should not be underestimated. For compounding pharmacies, the issue is no longer whether peptides present opportunity. The issue is whether that opportunity can be pursued without stepping outside the boundaries of federal law.

At the core of this discussion is the framework established under Section 503A of the Federal Food, Drug, and Cosmetic Act, which governs traditional pharmacy compounding. The rule itself is straightforward on paper. A pharmacy may compound using bulk drug substances only if those substances comply with a USP or NF monograph, are components of FDA-approved drugs, or appear on the FDA's 503A bulks list. The problem, of course, is that many peptides do not fit neatly into any of those categories.

This is where the distinction between Category 1 and Category 2 substances becomes critical. Category 1 substances are those that have been nominated with sufficient information and are under evaluation, and the U.S. Food and Drug Administration has historically exercised enforcement discretion with respect to their use. Category 2 substances, on the other hand, are a different story. These are substances that the FDA has flagged as presenting potential safety risks, and the agency has made clear that it does not intend to extend the same enforcement discretion.

Many peptides fall squarely into that Category 2 bucket.

From a legal standpoint, that should end the conversation. A substance that presents identified safety concerns and is outside the scope of enforcement discretion is not something a compounding pharmacy should be touching. But that is not how the market has evolved. Demand has continued to grow, fueled by patient interest, prescriber willingness and broader conversations around performance, longevity& and wellness.

That tension between regulatory structure and market demand is exactly what is driving the current push to move certain peptides from Category 2 into Category 1.

This is not speculation. It is already happening in real time. The FDA has been actively reviewing peptide nominations, and in some cases, substances have been removed from Category 2 and placed back into the evaluation pipeline for potential inclusion on the 503A bulks list. That process is slow, deliberate and heavily scrutinized, but it reflects a recognition that the current framework is not keeping pace with market realities.

At the same time, a broader narrative is developing outside the traditional regulatory process. When Robert F. Kennedy Jr. appeared on The Joe Rogan Experience, the discussion did not focus exclusively on peptides, but it did touch on a broader theme that should not be ignored. There is increasing skepticism around whether the current regulatory model is overly restrictive and whether certain compounds should be more accessible through alternative pathways.

More notably, there has been discussion around reclassifying a number of peptides from Category 2 into Category 1, effectively allowing compounding pharmacies to produce them under Section 503A. That is not a finalized policy, but it is not noise either. It is a signal.

For compounding pharmacies, the significance of that signal cannot be overstated. If even a portion of Category 2 peptides were moved into Category 1, it would materially change the landscape. Substances that are currently viewed as high-risk would suddenly fall within a framework where enforcement discretion is applied, and eventually, where formal inclusion on the bulks list becomes possible.

The question is how that transition happens.

There are realistically two paths. The first is through executive influence. The current administration could direct the FDA to prioritize the review and reclassification of certain peptides, or to adopt a more permissive enforcement posture while those reviews are ongoing. This would be faster, but it would also be less stable and more susceptible to reversal.

The second path, and the one that carries more long-term weight, is through formal rulemaking. This involves the FDA evaluating nominated substances, consulting with the Pharmacy Compounding Advisory Committee and ultimately determining whether those substances meet the criteria for inclusion on the 503A bulks list. It is a slow process, but once a substance is included, it provides a level of clarity that compounding pharmacies can rely on.

The FDA recently reminded compounders - again, but more pointedly - that strict conditions must be met to qualify for exemptions under Sections 503A and 503B. This is not a new law, but it is a clear signal of the enforcement posture.

Under 503A, the FDA emphasized that compounded drugs must be tied to a patient-specific prescription and cannot be compounded regularly or in inordinate amounts if they are essentially copies of commercially available drugs. The agency reinforced how it defines "essentially a copy," making clear that if the compounded product has the same active ingredient, similar strength and the same route of administration as an approved drug, it will be treated as a copy unless there is a documented clinical difference for a specific patient.

Importantly, the FDA went a step further by addressing combination products. The agency indicated that even adding another ingredient, such as vitamin B12 to semaglutide, will not avoid "copy" status if the overall formulation is still functionally substitutable. This directly targets one of the most common workarounds in the market.

The FDA also reiterated a narrow enforcement discretion threshold, stating it does not intend to take action if a pharmacy compounds four or fewer prescriptions per month of such a product. That is not a safe harbor. It is a ceiling.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.